



Dedicated To Life

November 16, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 16, 2022 titled "**Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast-an innovative prognostic test for breast cancer patients**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients

- *Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning*
- *Brings in 95% precision in gauging whether hormone positive breast cancer patients need chemotherapy or not*
- *This will benefit patients and clinicians pan India with a highly accurate and an evidence based approach for breast cancer treatment*
- *CanAssist Breast is a patented product of OncoStem, a research based startup headquartered in Bengaluru*

Ahmedabad, November 16, 2022

Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that it will be exclusively marketing CanAssist Breast, an innovative and a highly advanced prognostic test for breast cancer patients in the early stages to help clinicians decide whether the patient needs chemotherapy or not. Out of 2.1 lac breast cancer cases in India, almost 50 percent are hormone positive. In the absence of such prognostic tests, many patients undergo chemotherapy which may not help them. However, with the aid of CanAssist Breast and its precise findings, clinicians can avoid chemotherapy for their patients based on scientific evidence. OncoStem has developed this test after five years of research and has generated a lot of data on patients suffering from breast cancer in India and across the world.

Breast cancer is the leading cause of cancer in women in India and its risk increases with age. It is estimated that 1 in 29 women in India has a risk of developing breast cancer in her lifetime. Hormone receptor positive is the most common subtype of breast cancer and there are estimated 65000 new cases of early stage hormone positive breast cancer that get diagnosed every year. This test can help them to balance their treatment plan in terms of effect, cost and quality of life. There are no such tests currently performed in India. Clinicians send tissue samples to the US to avail similar test resulting in high cost burden and potential delay in treatment plan.

CanAssist Breast is a test to optimize treatment selection in early stage (I & II) hormone receptor positive, HER2 receptor negative type of breast cancer. It determines the patient's risk of breast cancer recurrence and classifies patient as 'low risk' or 'high risk' using proprietary Artificial Intelligence/ Machine Learning methods. CanAssist Breast spares patients of physiological



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878



Dedicated To Life

toxicity and is also patient-centric in terms of affordability as it is being made available at 80 percent lesser than the cost of global tests.

Speaking on this development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, “Zydus has been at the forefront of providing access to innovative and affordable therapies which also helps improve the quality of care for cancer patients in India. With this new offering we expand our offerings to include prognostic and diagnostic approaches that can greatly benefit cancer patients and clinicians. As a company dedicated to science, innovation and health, we are constantly looking at ways to empower people to live healthier and more fulfilled lives.”

Zydus Oncology

Zydus Lifesciences Ltd. is one of the leading players in the Oncology segment in India and has been at the forefront launching several First-in-India biosimilars and therapies. With a highly specialized and patient centric approach, the company has been able to bring access and affordability in cancer therapies. Six of the eight oncology pillar brands are leaders in their respective categories.

About Zydus

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 23,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

About OncoStem

OncoStem develops innovative prognostic tests that assess aggressiveness of tumours based on in-depth knowledge of tumour biology, to identify the unique characteristics of cancer recurrence risk. Since 2011, the company’s vision is to empower the doctors with evidence-based treatment plans with innovative prognostic tests. These actionable tests help physicians in formulating a customized treatment plan by understanding the tumour biology. Robust research is ongoing in the company’s laboratory to develop novel tests for other cancers. OncoStem has raised funds from Sequoia Capital and Artiman Ventures.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878